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PREFACE 
 
The Health Economics Research Group (HERG) at Brunel University is involved in a long-
term programme analysing the benefits from health research, with an emphasis on the 
payback from health services research. This programme is being expanded, in collaboration 
with colleagues working on these issues elsewhere, to include exploration of methodologies 
for assessing the impact from basic or early clinical biomedical research.  A central 
collaborator is Jonathan Grant, formerly Head of Policy at the Wellcome Trust, and now at 
RAND Europe.  In simultaneously publishing two reports as part of the HERG Research 
Report series we bring together several elements of this research, and draw on them to make 
proposals for further work. 
 
In HERG Research Report 30, From Bedside to Bench: Comroe and Dripps Revisited, Grant  
et al examine whether it is possible to replicate, and validate, the pioneering work of Comroe 
and Dripps in the 1970s.  The latter traced back from then current clinical practice to the 
knowledge behind the advances. They claimed that more than half of the articles identified as 
making a key contribution to the clinical advances resulted from basic research. The 
attempted replication proved difficult, but Grant et al describe how they developed and applied 
an alternative methodology. 
 
In HERG Research Report 31, From Bench to Bedside: Tracing the Payback Forwards from 
Basic or Early Clinical Research--a Preliminary Exercise and Proposals for a Future Study, 
Hanney et al describe a joint HERG/Wellcome Trust project that in part builds on the 
emerging findings from Grant et al’s study of the Comroe and Dripps methodology. 
Recognising the difficulties in tracing backwards from clinical practice, the project described 
here attempts instead to work forwards by tracing the impact from research conducted 20 
years ago. Having described how the methods were applied in a preliminary study, the report 
goes on to outline how the work could be developed in a larger study. 
 
The research undertaken for both reports was primarily funded by the R&D Directorate of the 
NHS Executive London, whose Director of R&D, Sally Davies, has been a stalwart supporter 
of such research and of its aim to provide an evidence-base for health research funding 
policies. 
 
Martin Buxton 
Health Economics Research Group 
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EXECUTIVE SUMMARY 
 
Twenty-five years ago a paper published in Science by Julius Comroe and Robert Dripps 
purported to demonstrate that 41 per cent of all articles judged to be essential for later clinical 
advances were not clinically oriented at the time of the study and 62 per cent of key articles 
were the result of basic research. 
 
Since that analysis, support for basic research has increased in the G7 countries.  In the UK, 
Research Council expenditure on basic research has increased from a low of £444 million (or 
42 per cent of total civil R&D) in 1991/92 to £769 million (or 61 per cent of total civil R&D) in 
1998/99.  Although it would be difficult to argue that Comroe and Dripps were directly 
responsible for a strategic shift (or drift) in the type of science supported by research funders, 
their arguments are often cited (albeit at times implicitly) in support of the increased funding 
for basic biomedical research. 
 
In 1987 Richard Smith wrote a critical paper reassessing Comroe and Dripps.  His main 
argument was that the original study was in itself ‘unscientific’ and that it should be “followed 
by bigger and better studies”.  This study is, in part, an answer to that challenge.   
 
Given the increased support for basic research, and the apparent importance based on the 
work of Comroe and Dripps, we felt it was important to investigate Smith’s comments by 
replicating Comroe and Dripps’s study and at the same time try to improve upon the 
methodology.  The current project had two objectives: 
1. To see if the original Comroe and Dripps’s methodology was ‘replicable’. 
2. To validate the key findings of Comroe and Dripps. 
 
By looking at neonatal intensive care (NIC), we concluded that Comroe and Dripps’ study – as 
reported – is not repeatable, reliable or valid, and thus is an insufficient evidence base for 
increased expenditure on basic biomedical research.  We did, however, develop an alternative 
methodology which used bibliographic databases and bibliometric techniques to describe the 
research underpinning five of the most important clinical advances in NIC, as identified 
through a Delphi survey. 
 
Using the revised bibliometric protocol, we demonstrated that after a time-lag of about 17 
years, between 2 and 21 per cent of research underpinning the clinical advances could be 
described as basic. This observation is at odds with Comroe and Dripps’s finding that 62 per 
cent of key research articles judged to be essential for latter clinical advance were the result 
iv 
of basic research.  
 
In reaching this conclusion we are acutely aware of the significant limitations to the revised 
methodology and, therefore, we caution against the over-interpretation of our results.  
However, we would argue that there needs to be a greater understanding of how basic 
research supports healthcare and hope this report will inform part of this wider debate. 
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CHAPTER 1: INTRODUCTION 
Twenty-five years ago a paper was published in Science which, arguably, would not meet 
today’s standards of peer-review.  All the same, the paper, by Julius Comroe and Robert 
Dripps, was a seminal piece of research.1  By examining the top ten key advances in the field 
of cardiovascular and pulmonary medicine and surgery they demonstrated that 41 per cent of 
all articles judged to be essential for later clinical advance were not clinically oriented at the 
time of the study and 62 per cent of key articles were the result of basic research. 
 
Yet, as with much of science policy, it would be wrong to see these results in isolation from 
the political debate at the time. The Comroe and Dripps study was inspired by a 1966 US 
Department of Defense study, Project Hindsight, that examined the effectiveness of basic 
research in the development of military weapons.2  This report concluded that: (a) 
contributions of university research were minimal; (b) mission-oriented research proved to be 
most effective; and (c) the time-lag between discovery and application was shortest when 
funding was focused. Consequently, in the USA, contract- and commission-initiated research 
became vogue.  For example, in 1966 President Lyndon Johnson said that “Presidents…need 
to show more interest in what the specific results of research are – in their lifetime, and in their 
administration.  A great deal of basic research has been done…but I think the time has come 
to zero in on the targets”.3, a 
 
Comroe and Dripps were concerned that applying lessons from military R&D policy to medical 
R&D policy was, in itself, invalid. So, they set out to design a study that provided a more 
objective basis for developing long-term policies to support biomedical research. Comroe and 
Dripps did this by identifying the ten most important clinical advances in cardiovascular and 
pulmonary medicine and then reviewing, with the help of experts, the medical literature 
relevant to the clinical advance.  They selected a set of key articles and, again with the help of 
experts, determined among other things, whether the key research was basic or clinically 
oriented at the time of the study.  
 
In addition to Comroe and Dripps’s response to Project Hindsight, the US National Science 
Foundation initiated the ‘Technology in Retrospect and Critical Events in Science’ study 
(TRACES).  TRACES methodology involves using historiographical tracings of key advances 
in a field in order to identify major technological innovations.  For example, in 1968 the US 
National Cancer Institute (NCI) published a study that evaluated the impact of research by 
research setting and funding mechanisms.4  Thirteen key advances in cancer research were 
traced back to papers which had a significant impact on their development and, where 
                                               
a  This quote is taken from the Introduction to the Comroe and Dripps’s study report. 
2 
relevant, to the NCI mechanism which supported the underlying research. The study 
concluded that research setting (e.g. large versus small institutes, universities versus medical 
schools etc.) did not have a major impact on the occurrence of advances. It also concluded 
that all NCI support mechanisms contributed significantly to the advances, with research 
project grant and an intramural programme being among the most effective. 
 
A decade later Richard Smith (formerly assistant editor, and now editor of the BMJ) wrote a 
critical paper reassessing Comroe and Dripps.5 His main argument was that the original study 
was in itself ‘unscientific’. Notwithstanding this, Smith concluded that “the real lesson from 
Comroe and Dripps – and I am sure that they understood this themselves – is that we need to 
research research so that we can allot funds in a more intelligent and less empirical and (to 
use their favourite word) anecdotal way”. He goes on to state that “sadly, Comroe and 
Dripps’s paper has not been followed by bigger and better studies” and that “the lessons from 
Comroe and Dripps have not been learnt to any great extent by those funding medical 
research”.  
 
The rise of basic research 
Despite Smith’s analysis, it seems that Comroe and Dripps’s conclusions entered the ‘psyche’ 
of policy makers in both Europe and North America, as support for basic research has been 
on the increase over the past decade. A comparison of gross expenditure on basic R&D in 
five countries is given in Figure 1.1.  It should be noted that these data are for all research 
areas by all funding sectors and include military R&D expenditure, the majority of which is 
classified as applied research. UK and Canadian data are unavailable for this OECD data 
series.  Figure 1.1 shows a general increase for support of basic research across the five 
countries, although it is interesting to note how the European countries are supporting more 
basic research than USA and Japan. That said, in the USA a recent report concluded that “in 
the late 1990s [research funding] agencies were tending to protect basic and university 
research relative to applied research and other performers”.6 
 
A similar trend is also apparent in the UK. This is illustrated in Figure 1.2 for civil UK Research 
Council expenditure on R&D by the Frascati categories.b  These figures are not directly 
                                               
b  The Organisation for Economic Co-operation and Development (OECD) provides the most reliable and consistent 
international analysis of R&D expenditures. In the Frascati Manual,b the OECD subdivides R&D into three related activities: 
basic research is experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying 
foundation of phenomena and observable facts, without any particular application or use in view; applied research is also 
original investigations undertaken in order to acquire new knowledge. It is, however, directed primarily towards a particular 
aim or objective; experimental development is systematic work drawing on existing knowledge gained from research and 
practical experience that is directed to producing new materials, products or devices; to installing new processes, systems or 
services, or to improving substantially those already produced or installed. 
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comparable with those presented in Figure 1.1 as they exclude non-Research Council 
expenditure (such as industry, medical charities, HEFCs etc.). Expenditure on basic research 
has increased from a low of £444 million (or 42 per cent of total civil R&D) in 1991/92 to £769 
million (or 61 per cent of total civil R&D) in 1998/99, while applied research has declined from 
a high of £683 million (or 58 per cent of total civil R&D) in 1992/93 to £486 million (or 38 per 
cent of total civil R&D) in 1998/99. 
 
Within the biomedical sciences, the major funders of biomedical science, such as the UK’s 
Medical Research Council (MRC) and the USA’s National Institutes of Health (NIH), all 
support a substantial amount of basic research. For example, the NIH has increased the 
budget of its General Medical Science (GMS) arm to a high of US$1.4 billion for Fiscal Year 
2001. The National Institute of GMS primarily supports basic biomedical research that is not 
targeted to specific diseases or disorders.7  
 
This trend is also noticeable in bibliometric data. For example, the proportion of basic 
biomedical research publications acknowledging the Wellcome Trust has increased by ten 
percentage points (from 47 per cent in 1989 to 58 per cent in 1998), while the trend for MRC-
acknowledged papers has stayed more constant from 48 per cent in 1988 to 50 per cent in 
1998 (Figure 1.3).8  At the same time, relative support for clinical research has declined: the 
proportion of Wellcome Trust-acknowledged papers that have a clinical address (i.e. at least 
one of the collaborators records an address with the strings ‘NHS’, ‘HOSP’ or ‘INFIRM’ in the 
address field) has fallen from 38 per cent in 1988 to 29 per cent in 1998 (Figure 1.4). 
 
While not wanting to give the impression that Comroe and Dripps were responsible for a 
strategic shift (or drift) in the type of science supported by research funders, their arguments 
are often cited (albeit at times implicitly) in support of the increased funding for basic 
biomedical research evidenced in Figures 1.1–1.4. 
 
Study objectives 
Given the increased support for basic research, and the apparent importance based on the 
work of Comroe and Dripps, we felt it was important to take up Smith’s challenge by 
replicating their study, but at the same time addressing Smith’s concerns by trying to improve 
upon the methodology. The current project had two objectives: 
1. To see if the original Comroe and Dripps’s methodology was ‘replicable’. 
2. To validate the key finding of Comroe and Dripps, that is to see if two-thirds of all research 
judged to be essential for later clinical advance could be described as basic. 
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Chapter 2 describes our attempt to repeat Comroe and Dripps, and concludes that their 
assumed protocol was not workable. Chapter 3 therefore describes an alternative, 
bibliometric, approach which we developed to build on the work we undertook in Chapter 2. 
The final chapter pulls together our findings, discusses a number of substantial 
methodological problems that are identified in the report and offers some policy 
interpretations. 
 
 
Figure 1.1:  Basic research as a percentage of the total of R&D spend for five  countries 
 
Source: Office of Science and Technology (2000). Science and Engineering and  
Technology Statistics, 2000. HMSO, Norwich 
 
 
 
Figure 1.2:  Analysis of UK Research Council expenditure by Frascati type of research 
activity 
 
 
Source: Office of Science and Technology (2000). Science and Engineering and Technology Statistics, 
2000. HMSO, Norwich 
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Figure 1.3: Proportion of papers published in basic biomedical research journals  
acknowledging Wellcome Trust (WT) and Medical Research Council (MRC) funding 
 
 
Source: Research Outputs Database 
 
 
 
Figure 1.4:  Proportion of papers acknowledging Wellcome Trust funding undertaken in 
a clinical setting 
Source: Research Outputs Database 
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CHAPTER 2: COMROE AND DRIPPS REVISITEDc  
 
The Comroe and Dripps study can be divided into three stages: the identification of clinical 
advances; the identification of key research articles which describe, in the language of 
Comroe and Dripps, the ‘essential bodies of knowledge’ that led to the clinical advance; and 
the analysis of these research articles in order to identify factors that lead to research 
success. 
 
Table 2.1 compares the methodology used by Comroe and Dripps with that developed in the 
current study.  The first difference is in the choice of field for investigation. Comroe and Dripps 
investigated cardiovascular and pulmonary medicine; we examined neonatal intensive care. 
We chose this field for several reasons: first, it has had a short but active history,9 with 
neonatal mortality rates declining in the UK from 59 infant deaths per 1000 live births in 1940 
to 7 in 1990;10 second, it has traditionally been an area of interest to the Wellcome Trust; third, 
the Trust held a Witness Seminar in Neonatology in April 1999, the participants of which 
provided an essential resource of expertise in developing the study.d, 11 
 
Table 2.1: Comparison of the Comroe and Dripps, and the current study 
 
Comroe and Dripps Current study 
Selected cardiovascular as field of study. Selected neonatal intensive care as field of study. 
Stage 1: Identified ten most important clinical 
advances via consultation with physicians. 
Identified ‘bodies of essential knowledge’ 
within these advances with the help of 
consultants (physicians, medical scientists, 
medical historians, etc.). 
Stage 1: Identified ten most important clinical 
advances via modified Delphi survey. Three rounds 
carried out. Sample included physicians, nurses, 
midwives, medical technologists and specialists. 
Identified ‘bodies of essential knowledge’ via internet 
search, advisory panel, sample of physicians. 
Stage 2: Reviewed medical literature for 
relevant journal articles. Identified ‘key article’ 
subset of 663 ‘important’ papers. Key article 
defined by Comroe and Dripps as having an 
important effect on the direction of 
subsequent research, or report new data, 
drugs or techniques. 
Stage 2: Searched Science Citation Index 1995–99 for 
relevant articles. The articles collected became 
generation 1.  All the articles cited by the papers of 
generation 1 were collected, and ranked by the 
number of times they were cited. The top 5 per cent of 
the articles cited became generation 2. This process 
was repeated until four generations of articles had 
been collected. 
Stage 3: Analysed key articles as to the 
percentage that could be classified as basic 
research, clinically oriented research, funding 
source etc. 
Stage 3: Analysed the four generations of articles 
using bibliometric techniques. Articles were classified 
as describing either basic or clinical research.  
 
                                               
c  This critique draws heavily on the work of Smith (1987) (reference 5). 
d  A witness seminar is a vehicle used by the Wellcome Trust Centre for the History of Medicine at UCL’s History of Twentieth-
century Medicine Group to bring academics and clinicians together to discuss the history of a particular therapeutic area or 
treatment. The transcripts of these seminars are published as an oral history (see www.ucl.ac.uk/histmed). 
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Stage 1 – Identification of clinical advances 
In stage 1, Comroe and Dripps identified the essential bodies of knowledge around 
cardiovascular clinical advances. Forty physicians were asked to list what they considered to 
be important advances in their field. Comroe and Dripps compiled their responses into lists 
that were submitted to a further sample of ‘40 to 50 specialists’ in cardiovascular and 
pulmonary medicine, who were asked to vote for the most important advance. However, as 
Smith points out, we do not know how they chose the initial 40 physicianse and the 40–50 
specialists; what were the respective response rates (did they ask more than 40 physicians, 
and only 40 replied or did they ask 40 and fewer replied?); and what method of voting was 
used and how were the votes tallied? Nevertheless, the responses were tabulated and the ‘top 
ten’ list of advances was developed, as illustrated in Table 2.2. 
 
 
Table 2.2: The top ten clinical advances in cardiovascular and pulmonary medicine and 
surgery in the last 30 years 
 
Advance Comprising 
Cardiac surgery Including open-heart repair of congenital defects and 
replacement of diseased valves 
Vascular surgery Including repair or bypass of obstructions or other lesions in 
aorta, coronary, cerebral, renal and limb arteries 
Drug treatment of hypertension  
Medical treatment of coronary 
insufficiency 
Myocardial ischaemia 
Cardiac resuscitations Including defibrillation, cardioversion and pacing in patients with 
cardiac arrest, slow hearts, or serious arrhythmias 
Oral diuretics In treatment of patients with congestive heart failure or 
hypertension 
Intensive cardiovascular and 
respiratory care units 
Including those for postoperative care, coronary care, 
respiratory failure,  
and disorders of the newborn 
Chemotherapy and antibiotics Including prevention of acute rheumatic fever and treatment of 
tuberculosis,  
pneumonias and cardiovascular syphilis 
New diagnostic methods For earlier and more accurate diagnosis of disease of 
cardiovascular and  
pulmonary-respiratory systems 
Prevention of poliomyelitis Especially of respiratory paralysis due to polio 
 
We tailored this methodology by employing three rounds of a modified Delphi survey to 
identify the leading advances in neonatal intensive care. In the first round, participants and 
attendees (n = 41) of the Wellcome Trust Witness Seminar in Neonatology were asked to 
                                               
e  In the report (reference 3), Comroe and Dripps have a footnote saying that the physicians are listed in the August 1975 
Preliminary Report to the National Heart and Lung Institute, but we have been unable to trace this publication. 
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propose major advances in neonatal intensive care and to suggest a definition of NIC.10 The 
21 responses (response rate = 58 per cent) were compiled into a pilot questionnaire that was 
sent to a sample of 19 individuals who were invited, but did not participate, in the Witness 
Seminar and 50 randomly selected practising neonatal/paediatric healthcare providers 
identified in The Neonatal Nurses Association Yearbook.f, 12 The 69 survey participants were 
requested to vote for their top ten advances, and to add any they felt had been omitted. The 
31 responses (response rate = 45 per cent) were then used to develop the final questionnaire 
(see Appendix A), which was sent to the balance (n = 1758) of neonatal/paediatric healthcare 
providers within the UK.g A response rate of 45 per cent was achieved in the final, third round 
of the Delphi survey. A simple counting of votes prioritized the list of advances (Figure 2.1 and 
Table 2.3).  
 
We were conscious that the professional background of the respondents and their experience 
in the field may have had some effect on the ranks. However, as illustrated in Tables 2.3, with 
some minor exceptions, this proves not to be the case and therefore we restricted our 
analysis to the global list. 
 
There were, however, a number of complications with the Delphi survey which were pointed 
out by final round participants. First, there were a few choices that could be considered to be 
closely overlapping. For example it was mentioned that the choices of ‘incubator’ and 
‘temperature control’ were to all intents and purposes the same, as were ‘light therapy’ and 
‘control of jaundice’. Second, due to an office error, antenatal steroids appeared twice in the 
final questionnaire (and thus could be one of the reasons why it was voted number three on 
the list). Third, the inclusion of antenatal steroids seemed to be inappropriate as their purpose 
was to prevent NIC. Finally, there was some concern that the definition we used for neonatal 
intensive care was too broad.  
 
Although these criticisms of the Delphi survey may be just, we would argue that they do not 
undermine the study, as its primary purpose was to understand how basic research fed into 
clinical advances that had impacted on healthcare. The Delphi survey provided us with a 
method of identifying a shortlist of high-impact clinical advances. We therefore decided to take 
the top three advances (mechanical ventilation, replacement surfactant and antenatal 
steroids) and, following discussions with our sponsors,h parenteral nutrition and ultrasound 
                                               
f  The healthcare professionals were randomly selected from a list of all neonatal and paediatric intensive care units in the UK 
published in The Neonatal Nurses Association Yearbook (reference 12). 
g  In order to assure that the actual rank of the advances in the questionnaire did not influence the respondents’ answers, five 
sets of questionnaires were developed each with a different ordering of the list. 
h  The R&D Directorate of the London regional office of the NHS. 
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(see Box A for a description of these advances) for further study. 
 
Figure 2.1: Leading advances in neonatal intensive care 
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Table 2.3: Top ten advances in neonatal intensive care – overall ranking, by profession 
and by years of experience 
 
Advance Total 
votes 
Rank Clinical Nursing Managers 1–10 years’ 
experience 
11–20 
years’ 
experience 
20+ years’ 
experience 
Mechanical ventilation 643 1 1 4 1 1 1 1 
Replacement surfactant 589 2 2 1 3 2 2 2 
Antenatal steroids 577 3 3 2 2 3 3 3 
Neonatology as 
subspecialty 
517 4 4 3 4 4 4 4 
Neonatal intensive  
care units 
384 5 6 7 5 5 6 5 
Parenteral nutrition 371 6 5 8 6 7 5 6 
Physiology of neonate 351 7 7 6 7 6 7 7 
Resuscitation techniques 300 8  5 8 8 8 10 
Temperature control 286 9 9  9  10  
Ultrasound imaging 264 10     9 8 
 
 
Box A: Glossary of selected clinical advances 
 
Mechanical ventilation  If a neonate is unable to breath normally, a mechanical ventilator can be 
used to maintain a flow of air into and out of the patient’s lungs. 
Development of 
replacement surfactant 
 Surfactant is a wetting agent consisting of a complex mixture of 
compounds that prevent the air sacs of the lungs from collapsing by 
reducing surface tension. Its absence, such as in immature lungs of 
premature babies, leads to atelectasis (the failure of the lung  
to expand) and respiratory distress syndrome (RDS). Replacement 
surfactant can help treat these conditions. 
Use of antenatal steroids  This is the practice of giving a single course of corticosteroids to 
pregnant women between 24 and 34 weeks’ gestation who are at risk 
for preterm delivery. The drugs, administered intramuscularly, 
accelerate the maturation of fetal lungs and other organs, and reduce 
the risk of respiratory distress syndrome (RDS), brain haemorrhage, and 
mortality in preterm infants. 
Total parenteral nutrition 
(TPN) 
This is providing the body’s nutritional needs by a balanced mixture of 
basic constituents supplied by intravenous infusion. 
Ultrasound imaging  A diagnostic procedure that projects high-frequency sound waves into 
the body and changes the echoes into pictures (sonograms) shown on a 
monitor. Different types of tissue reflect sound waves differently. This 
allows detailed anatomical images to be built up that can assist with 
diagnosis in the fetus and neonate. 
 
 
NB. The descriptions used in this glossary are the same as those identified and used in the 
Delphi survey (Appendix A), although in the text of the report short descriptions are used. 
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Stage 2 – Review of literature supporting clinical advances 
Once Comroe and Dripps had identified the top ten advances, they worked with external 
consultants to identify the “essential bodies of knowledge that we believe had to be developed 
before each of the 10 clinical advances could reach its present stage of achievement”. It 
appears that 144 consultantsi were involved in this process; however, the depth or format of 
consultation was not explained, although they indicate that 46j of the consultants were 
interviewed (suggesting that the other 98 were surveyed). 
 
From their consultations, Comroe and Dripps identified 137 ‘essential bodies of knowledge’ 
that were needed for the advance to occur. (As an example, Table 2.4 illustrates the essential 
bodies of knowledge required for open heart surgery.) They ‘examined’ 4000k articles on 
cardiovascular/pulmonary medicine, ‘identified’ 2500l of them for special consideration. How 
the initial review was carried out, or how articles were identified as relevant, is not explained. 
Comroe and Dripps then arranged the “specific scientific reports that were particularly 
important for the development of one or more of the 137 essential bodies of knowledge” into 
chronological tables. 
 
Comroe and Dripps went on to select 529 ‘key articles’.m  Key articles were those articles 
which Comroe and Dripps, with the help of consultants, considered to be essential for one or 
more of the top ten clinical advances because: 
• “It had an important effect on the direction of subsequent research and development, 
which, in turn proved to be important for clinical advance in one or more of the ten clinical 
advances under study.” 
• “It reported new data, new ways of looking at old data, a new concept or hypothesis, a 
new method, a new drug, or a new technique that either was essential for full development 
of one or more of the clinical advances (or necessary bodies of knowledge)…” 
• “A study is not a key study if it has not yet served directly or indirectly as a step towards 
solving one of the ten clinical advances.” 
• “An article is a key article if it described the final step in the clinical advance.” 
                                               
i  The reporting of a number of figures vary between the paper (reference 1) and the report (reference 3). For example, the 
paper refers to 144 consultants while the report puts this number at 166. In this analysis we use the figures cited in the 
paper, but footnote those in the report. We assume these differences are because the report was published in 1977 and the 
paper 1976, hence allowing further analysis and updates of late responses etc. 
j  49 in report (see footnote i). 
k  6000 in report (see footnote i). 
l  3400 in report (see footnote i). 
m  663 in report (see footnote i). 
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Table 2.4: Essential bodies of knowledge required for successful open-heart surgery 
 
Preoperative diagnosis of 
cardiac defects 
Anatomic and clinical 
Physiologic: electrocardiography, other noninvasive 
tests 
Physiologic: cardiac catheterization 
Radiologic: selective angiocardiography 
Preoperative care and 
preparation 
Blood groups and typing: blood preservation; blood 
banks  
Nutrition  
Assessment of cardiac, pulmonary, renal, hepatic and 
brain function 
Management of heart failure 
Intraoperative management Asepsis 
Monitoring ECG, blood pressure, heart rate, ECG and 
blood O2 and pH 
Anaesthesia and neuromuscular blocking agents 
Hypothermia and survival of ischemic organs  
Ventilation of open thorax  
Anticoagulants 
Pump-oxygenator 
Elective cardiac arrest; defibrillation 
Transfusions; fluid and electrolytes; acid–base balance 
Surgical instruments and materials  
Surgical techniques and operations 
Postoperative care Relief of pain 
General principals of intensive care; recording and 
warning systems 
Management of infection 
Diagnosis and management of circulatory failure 
Diagnosis and management of other postoperative 
complications 
Wound healing 
 
 
Comroe and Dripps took 42 (of the 137) chronological tables and, using the above 
description, identified the ‘key articles’. They also sent the same table to reviewers for their 
independent selection (with, one assumes, their definition of a key article). Again, we do not 
know why there were 42 tables and how they were selected. We do not know the make-up of 
the reviewers. Tellingly, in a footnote to a table analysing the reviewers and their classification 
of key articles, Comroe and Dripps note that “the total number of key articles selected by 
reviewers is higher than the number selected by us because (i) the reviewers on average 
selected 8.4 key articles per table and we selected on average only 6.7 for these 42 papers; 
and (ii) we sent some tables to more than one reviewer”.  Unfortunately we do not know the 
inter-rater reliability of Comroe and Dripps and the independent reviewers.  Nevertheless, 
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Comroe and Dripps went on to use the 529 key articles to form the basis of their analysis.  
We tried to refine Comroe and Dripps’s approach by drawing up ‘developmental maps’ that 
identified both key events and key researchers in the development of a clinical advance.n 
These would be our equivalent of the chronological tables of key bodies of knowledge. We 
began to do this for the first three advances on our list – mechanical ventilation, artificial 
surfactant and antenatal steroids (see Figures 2.2–2.4 for our draft attempts). The maps were 
based on desk research (undertaken by Barbara Mason) using Internet, bibliographic 
databases, review papers etc. The development maps were then modified on the basis of 
discussions with three experts in the field.o Finally, the modified maps were sent to a random 
sample of 15 participants (response rate 4/15, 27 per cent) from the final round of the Delphi 
survey for comments, which we planned to incorporate in the final road map, after 
consultation with the advisory panel.p  
 
It was at this stage that we had to address two seemingly insoluble problems which, given the 
preceding ambiguities, began to undermine the whole study. First, how does one define an 
‘essential body of knowledge’? Comroe and Dripps used a fairly flexible definition: “as 
knowledge that we believe had to be developed before each of the 10 clinical advances could 
reach its present state of achievement”. The trouble with this definition is that if it is applied 
rigorously, it results in a generic path from a basic discovery, through animal trials to human 
trials to clinical practice (as illustrated in Figures 2.2–2.4). If a less stringent interpretation is 
used, it is difficult to contain the path that would extend from biomedical science to statistics, 
engineering and research methods. For example, in studying the development of antenatal 
steroids it become apparent that the knowledge had existed within the clinical community for 
some time, but was only comprehensively implemented – and thus became an advance – 
when a meta-analysis systematically13 combined a number of previous trials (Figure 2.3). In 
this case, therefore, the statistical methodology developed by Peto and colleagues14, 15 for 
combining trial data was an essential body of knowledge. 
 
Our second major concern was how can the scientific publications associated with an 
essential body of knowledge be systematically identified? That is, how can we identify a set of 
scientific publications which, using an identical research protocol, would also be selected by 
another independent investigator? Our initial approach was to use searchable bibliographic 
databases to locate articles around the essential bodies of knowledge for each advance. 
However, we soon discovered that this approach was not workable in a systematic way, as 
                                               
n  This work draws on the historiographical TRACES study (reference 4). 
o  See Acknowledgements for names. 
p  If we had continued with this approach, we would have circulated the draft maps to a wider sample, but at this stage we were 
simply piloting the methodology. 
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the sample would ‘snowball’ in an unpredictable – and thus potentially unrepeatable – manner. 
 Furthermore, we were at a loss to know how to determine, again in a systematic, repeatable 
way, which researchers and papers were more ‘essential’ or ‘key’ than others.  
 
Given Smith’s original comments, it is perhaps not surprising that we found ourselves 
questioning whether the study was feasible. Indeed, it could be argued that we should not 
have tried to repeat Comroe and Dripps’s methodology in the first place. By trying to repeat it 
we had hoped to be able to work our way through some of the issues Smith had highlighted 
but, as described, found this not to be possible. We therefore concluded that we could not 
repeat the Comroe and Dripps study, as set out in their reports, but were in a position to take 
forward a revised methodology which built on the results of the Delphi survey and utilized 
today’s bibliographic resources in identifying the scientific basis of clinical advances. 
 
Stage 3 – Analysis of ‘key articles’ 
For the sake of completing the story, Comroe and Dripps analysed the 529 ‘key articles’ by 
assessing whether the goal of the research was clinically oriented or not (Table 2.5). 
Research was clinically oriented “if the author, anywhere in his paper (excluding speculation at 
the end of his article), mentions, even briefly, an interest in diagnosis, treatment or prevention 
of a clinical disorder or in explaining the basic mechanisms of a sign or symptom of the 
disease itself…even if this research was performed entirely on animals, tissues, cells or 
subcellular particles”. Research was not clinically oriented “if the authors…never state or 
suggest any direct or indirect bearing that their research might have on a clinical disorder of 
man”.  
 
They also assessed whether the key articles described basic research, and defined this as to 
mean research “when the investigator, in addition to observing, describing and measuring, 
attempts to determine the mechanism responsible for the observed effects”. Having settled on 
this definition, Comroe and Dripps used six categories to analyse the key articles and showed 
that the total number of studies in basic research, either unrelated or related to a clinical 
problem, was 62 per cent of the total number of entries (Table 2.6). 
 
The study does not explain what steps were taken to ensure the validity of the categorization 
process. Was each article rated by each of them, and consensus reached? If not, inter-rater 
variability must be expected.  Comroe and Dripps themselves admitted that many articles did 
not fit neatly into one category or the other, and that the expectations of the analyst would 
colour the results of the process.  
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Summary 
We concluded that the Comroe and Dripps methodology cannot be repeated without making 
fundamental changes to the study design; these are changes of such a magnitude that a 
comparison between our results, and those obtained by Comroe and Dripps would be of 
dubious value. However, at this stage of the research study, we had identified the leading 
clinical advances in neonatal intensive care, developed draft ‘maps’ for three of these 
advances and begun to identify papers underpinning these developments. We decided that it 
would be a missed opportunity not to use these data as the basis for a revised study looking 
at the relationship between basic research and healthcare. 
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Figure 2.2:  Draft ‘map’ illustrating the development of mechanical ventilation 
 
 
Modern ventilation methods: 
CPAP; high frequency;  
oscillating 
Discovery of the role of 
surfactant, development of 
surfactant replacement therapy 
 
 
The development of  
positive and negative pressure 
ventilators for babies, cycled  
either by volume or pressure  
of gas entering lungs 
 
Development of 
tracheotomy techniques and 
tubing 
 
 
Development of ventilators  
for adults 
Recognition of incomplete 
formation of pulmonary 
system in small neonates 
Pathology of babies –  
identification of those  
requiring ventilation 
Recognition of  
O2 toxicity and 
trauma caused  
by mechanical 
ventilation 
Monitoring methods for 
arterial blood gases  
(invasive, noninvasive) 
Independent control of blood 
gas levels 
 
Development of ventilator 
triggering/control devices 
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Figure 2.3:  Draft ‘map’ illustrating the development of artificial surfactant 
 
 
 
 
 
 
 
Measurement of surface tension 
 
 
PV curves 
Proof of existence of surfactant 
 
Pathology of dead babies 
Identify RDS/hyaline membrane disease 
Development of artificial surfactants: 
Animal and synthetic 
Tailoring to make them work 
 
 
Human trials 
 
 
Animal experimentation 
 
 
Commercial drivers – 
pharmaceutical companies 
 
Description and characterization of 
surfactant and RDS 
 
Study of pulmonary function  
and gas exchange 
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Figure 2.4:  Draft ‘map’ illustrating the development of antenatal steroids 
 
 
 
 
 
 
 
 
Use of steroids for other  
lung diseases 
 
 
Animal trials looking at the effect  
of steroids on pulmonary function 
 
 
 
 
Meta-analysis 
 
Long-term development of 
problems 
 
Use of steroids for other  
lung diseases 
 
 
Royal College of Obstetricians: 
Green Sheet 1995 
 
Human trials looking at the effect  
of steroids on pulmonary function 
 
Fetal, neonatal and parturition 
research based on studies of  
sheep and rabbits 
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Table 2.5: Goal of authors of 529 key articles that later were judged to be essential for a 
clinical advance (taken from Comroe and Dripps, 1976) 
 
Clinical advance Clinically oriented 
Not clinically 
oriented Total 
% of total of non-
clinically oriented 
Cardiac surgery 
Vascular surgery 
Hypertension 
Coronary insufficiency 
Cardiac resuscitation 
Oral diuretics 
Antibiotics 
New diagnostic methods 
Poliomyelitis 
53 
40 
35 
44 
24 
19 
40 
41 
16 
35 
8 
44 
21 
16 
24 
13 
53 
3 
88 
48 
79 
65 
40 
43 
54 
94 
19 
39.8 
16.7 
55.7 
32.3 
40.0 
55.8 
24.5 
56.4 
15.8 
Total 312 217 529 41.0 
 
 
 
Table 2.6: Type of research reported in 529 key articles (taken from Comroe and Dripps, 
1976) 
 
Clinical advance 
Basic 
research 
not 
clinically 
oriented 
Basic 
research 
clinically 
oriented 
Other 
clinically 
oriented 
studies 
Review of 
synthesis 
Development or 
engineering for 
research use 
Development or 
engineering for 
clinical use 
Total 
Cardiac surgery 
Vascular surgery 
Hypertension 
Coronary insufficiency 
Cardiac resuscitation 
Oral diuretics 
Antibiotics 
New diagnostic 
methods 
Poliomyelitis 
34 
9 
42 
21 
16 
23 
12 
49 
3 
23 
7 
16 
20 
11 
13 
18 
21 
12 
19 
14 
21 
22 
9 
6 
21 
5 
3 
0 
3 
2 
1 
0 
1 
1 
2 
0 
3 
0 
0 
1 
0 
0 
0 
17 
1 
11 
21 
0 
3 
6 
3 
2 
22 
0 
90 
54 
81 
68 
42 
43 
54 
116 
19 
Total 209 141 120 10 22 65 567 
% of total 37 25 21 2 4 11  
 
NB. The total (567) exceeds the number of papers reviewed as some papers can fit into more 
than one category. 
 
20 
CHAPTER 3: HOW DOES BASIC SCIENCE SUPPORT CLINICAL RESEARCH? 
 
Our main motive for trying to repeat Comroe and Dripps’s study was to improve our 
understanding of how basic biomedical research feeds into and supports the development of 
clinical practice. Therefore, once we had reached the conclusion that, given the information 
provided in Comroe and Dripps’s paper and report, we could not repeat their analysis, we re-
appraised our approach and came up with a different methodology. In short, we felt that, using 
bibliographic databases and bibliometric techniques, we could evaluate how much basic 
research is underpinning the clinical advances that we identified in the Delphi survey. It must 
be remembered that Comroe and Dripps did not have access to the databases and 
techniques that we describe and utilize in this new analysis.  
 
In this chapter we describe the revised methodology and the results of the analysis. In the 
final chapter we draw out a number of conclusions from this and the previous chapter and 
assess the policy implications of our analysis. 
 
Bibliometric data and methodology 
We decided to use the same methodology that we had developed for assessing the scientific 
basis of clinical practice guidelines.16, 17 Just as it is possible to build up a family tree by 
identifying a child’s parents, grandparents and so on, it is possible to create a ‘genealogy’ for 
a clinical practice guideline or, in the current case, for a clinical advance, using citation 
analysis as illustrated in Figure 3.1. Once the ‘genealogy’ has been mapped, it is then 
possible to undertake bibliometric analysis on the cited papers at the different ‘generations’.  
 
For five clinical advances – mechanical ventilation, replacement surfactant, antenatal steroids, 
parenteral nutrition and ultrasound – we searched the Science Citation Index (SCI) for the 
years 1995–99 inclusive. This timescale was selected in order to collect a contemporary set of 
papers for each advance with a time span that would generate a sufficient number of papers 
to analyse. The search was made using the filter for neonatology developed in-house (see 
Annex B1), amended to limit the articles identified to the subject of interest by inserting key 
words, such as ‘mechanical ventilation’, ‘mechanical respiration’, ‘replacement surfactant’, 
‘artificial surfactant’, ‘antenatal steroids’ and ‘corticosteroid’ (as illustrated in Annex B3). In the 
case of antenatal steroids, we combined the neonatalogy filter with the obstetrics/gynaecology 
filter (Annex B2) as antenatal steroids are provided to the expectant mother.  
 
The articles identified via this search were labelled generation 1. The references contained in 
each of the generation 1 articles were collected and arranged in descending order, based on 
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the number of times each had been referenced. The top 5 per cent of these papers formed 
generation 2.q By selecting the most cited papers we assumed that they were high impact and 
of importance to the development of the clinical advance. This methodology was repeated 
twice more, resulting in four ‘generations’ of articles per advance. Thus generation 1 contains 
the most recent papers (dating from 1995–99) while generation 4 contains the oldest papers, 
some dating from decades ago.  
 
All the papers (i.e. generation 1, 2, 3 and 4 papers) were either looked up on the SCI or in 
libraries. Detailed bibliographic information was imported or entered into a bespoke database. 
In addition, all the papers were looked up in libraries to determine their funding sources by 
using standard methodology developed by the Wellcome Trust’s Policy Unit.8 Extramural 
funding was taken from the formal acknowledgements section, (e.g. “We thank the Wellcome 
Trust for funding this study”), and intramural funding from the addresses (e.g. the MRC’s 
National Institute for Medical Research in London). Funding bodies were classified into three 
main sectors: government (GOV), private-non-profit (PNP), and industry (IND). If the paper 
was not indexed on the SCI, then the extra or missing information (such as addresses, titles 
etc.) were also noted. 
 
Analysis was based on either paper or journal details, and included examination of: (a) the 
knowledge cycle time, i.e. the time between a paper’s publication and its citation by another 
paper in the ‘parent’ generation; (b) the country of authorship, based on analysis of the 
address fields; (c) the type of cited research, that is the extent to which the papers describe 
basic (or clinical) research; (d) the research setting, that is whether in a university or hospital 
or both, based on analysis of the address fields; and (e) source of funding, as measured by 
acknowledgements on papers. 
 
The third analysis (i.e. c above) used a journal classification system developed and updated 
by CHI Inc., which is based on expert opinion and journal-to-journal citations, and has become 
a standard tool in bibliometric analyses.18  Journals are allocated into four hierarchical levels 
in which each level is more likely to cite papers in journals at the same level or the level below 
it and vice versa. Hence, only 4 per cent of papers in level 1 ‘clinical observation’ journals (e.g. 
British Medical Journal) will cite papers in level 4 ‘basic’ journals (e.g. Nature), compared to 8 
per cent for level 2 ‘clinical mix’ journals (e.g. New England Journal of Medicine), and 21 per 
cent for level 3 ‘clinical investigation’ journals (e.g. Immunology). By looking at the journals in 
which papers cited on clinical advances are published, it is possible to characterize the 
                                               
q  In selecting the top 5 per cent, all papers that had been referenced an equal number of times to those in the mathematical 
top 5 per cent were also included. Therefore most generations of articles contain slightly more than 5 per cent of the article 
population. 
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research and estimate how long it takes for basic research to feed into clinical practice.  
 
We adopted this approach as it eliminated the threat of rater bias, and allowed us to use a 
transparent, systematic and generally accepted method of identifying basic research. It also 
removes the hurdle of building our own definition of basic research. There are, however, two 
caveats. First, we made the assumption that the research levels of the journals have 
remained constant over time. Second, this type of analysis remains rather crude as it 
allocates all papers within a journal to one level, despite a strong likelihood that there is 
variation in the type of research published in any given journal.  
 
Results from the bibliometric analysis 
The number of articles identified and analysed, by advance and generation, is given in Table 
3.1. The first row in this table (‘Papers identified using SCI search, 1995–99’) gives the first 
generation of papers.  These were identified using the neonatology filter (and in the case of 
antenatal steroids, also the obstetrics and gynaecology filter), along with the advance-specific 
key words listed in Table 3.2.  The second set of data refers to generation 2 papers, the third 
set to generation 3 papers and the fourth set to generation 4 papers. Duplicate papers were 
removed since a number of the generation 2 papers, for example, would have been cited 
more than once by different generation 1 papers. The number of times a paper was cited was 
recorded and those 5 per cent of papers that were referenced the most were then selected 
and used for the analysis. By selecting the most cited papers we assumed that they were high 
impact and of importance to the development of the clinical advance. In the case of 
replacement surfactant this means that the 321 generation 1 papers referenced 12 747 
generation 2 papers, of which 5402 were unique (i.e. there were 12 747 – 5402 = 7345 
duplicate references).  If these 5402 papers were listed in descending order of the number of 
times they were cited, then the top 270 papers would fall within the fifth percentile. However, 
as the fifth percentile dissected papers which had been cited seven times, the citation 
boundary was extended to include all such papers (i.e. 306 in the case of replacement 
surfactant). 
 
Table 3.1 also shows that the number of papers identified in generation 1 ranged from 321 
(for replacement surfactant) to 58 (for total parenteral nutrition).  As can be seen in Figure 3.2, 
the replacement surfactant advance actually grew (in terms of publication output) over the 
four generations of analysis, while the total parenteral nutrition stayed stable. In contrast, 
outputs in antenatal steroids and ultrasound decline over the four generations of analysis. 
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Table 3.1: The number of papers, references and duplicate papers per generation by the 
five clinical advances 
 
 Mechanical 
ventilation 
Replacement 
surfactant 
Antenatal 
steroids 
Parental 
nutrition 
Ultrasound 
      
Papers identified using SCI search for 1995–99 281 321 291 58 121 
      
Total reference from generation 1 papers 7949 12 747 9063 1805 3147 
Total unique references 5367 5402 6615 1432 2574 
Top 5% of papers  281 306 392 77 352 
Found papers 274 304 379 63 274 
Citation boundary 4 7 3 3 2 
      
Total reference from generation 2 papers 8157 10 295 15 040 1477 8711 
Total unique references 4928 4660 10 345 1130 5460 
Top 5% of papers  256 261 854 75 339 
Found papers 250 250 800 61 279 
Citation boundary 5 7 3 3 4 
      
Total reference from generation 3 papers 6548 10 332 29 545 1293 7867 
Total unique references 3574 4669 17 289 1025 4453 
Top 5% of papers  183 226 926 58 244 
Found papers 180 215 875 51 201 
Citation boundary 6 7 5 3 5 
 
 
Figure 3.1: Tracing the ‘research tree’ 
 
 
 
 
 
 
 
SCI 
 
Generation 2 
Generation 1 
Generation 3 
Generation 4 
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Figure 3.2: Number of papers per generation by advance 
MV= mechanical ventilation; RS = replacement surfactant; AS = antenatal steroids; PN = parenteral 
nutrition; and UL = ultrasound 
 
Knowledge cycle time 
Previously we defined the knowledge cycle time as the median time between two generations 
of papers.15,16  This is illustrated in Figures 3.3a to 3.3e, which plot the number of papers 
published each year for each generation. For replacement surfactant (Figure 3.3b), the 
knowledge cycle time between generations 1 and 2 is five years (i.e. the difference between 
the median date of publication for the first generation, which is 1996, and the median date of 
publication for the second generation, which is 1991). It should be noted that the first 
generation papers are truncated, in the sense that we only looked at papers indexed on the 
SCI CD-ROMs for 1995–99, and that the second and subsequent generation represent those 
top 5 per cent of cited papers. Hence the point of real interest is the time between each 
generation of publication. This is summarized in Table 3.2, where the median publication date 
for each generation for the five clinical advances is tabulated. The overall time between 
generations 1 to 4 ranges from 13 years (for artificial surfactant) to 21 years (for parenteral 
nutrition). The other three advances took 17 years to develop through four generations of 
citations. It is worth remembering that we have only gone back four generations and therefore 
the knowledge cycle time is only for generations 1 to 4, and other generations (i.e. 5,6,7 etc.) 
would extend the time horizon. 
 
0
200
400
600
800
1000
G4 G3 G2 G1
Generation
N
u
m
be
r 
o
f p
ap
er
s
MV
RS
AS
PN
UL
25 
Table 3.2:  Median age of publication 
 
Generati
on 
Clinical advance 
Mechanical 
ventilation 
Replacemen
t surfactant 
Antenatal 
steroids 
Parenteral 
nutrition 
Ultrasound 
G1 1997 1996 1997 1997 1997 
G2 1990 1991 1991 1988 1998 
G3 1985 1986 1985 1981 1984 
G4 1980 1983 1980 1976 1980 
 
 
 
 
Figure 3.3a: Number of papers per generation of mechanical ventilation by year of 
publication 
 
G1 refers to generation 1; G2 to generation 2 and so on. 
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Figure 3.3b:  Number of papers per generation of replacement surfactant by year of 
publication 
 
 
G1 refers to generation 1; G2 to generation 2 and so on.  
 
 
 
Figure 3.3c: Number of papers per generation of antenatal steroids by year of 
publication 
 G1 refers to generation 1; G2 to generation 2 and so on. 
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Figure 3.3d: Number of papers per generation of parenteral nutrition by year of 
publication 
 
G1 refers to generation 1; G2 to generation 2 and so on. 
 
 
 
Figure 3.3e: Number of papers per generation of ultrasound by year of publication 
G1 refers to generation 1; G2 to generation 2 and so on. 
 
 
Country of authorship  
Table 3.3 shows the distribution of papers by the country of the author and the generation of 
citation for the five clinical advances. The first row provides comparison data for 1998 taken 
from the SCI using a title keyword and specialist journal search strategy developed for 
biomedicine and described elsewhere.19 This shows that approximately four in ten biomedical 
research papers are authored by Americans, and one in ten papers by UK and Japanese 
scientists. By comparing the expected proportion of papers (i.e. outputs in 1998 by country) 
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with those first-generation papers, it is possible to identify those countries which have a 
comparative research advantage for a particular advance. For example, Canada and the UK 
are particularly strong in research supporting parenteral nutrition – Canada produces nearly 
five times more papers than expected (i.e. 23/5), and the UK more than twice as much as 
expected (i.e. 25/10). Conversely the USA and the other G7 countries are weak in this area. A 
second observation to be made from Table 3.3 is that the contribution from the USA declines 
from the oldest (generation 4) papers to the most recent (generation 1) papers by between 22 
(mechanical ventilation) and 41 (parenteral nutrition) percentage points over the four 
generations analysed.  
 
Type of research 
The next analysis was based on the journals in which each generation of papers was 
published, and was used to determine the extent to which basic or clinical research 
underpinned the five clinical advances. The papers were split into four categories or levels: 
level 1 (clinical observation), level 2 (clinical mix), level 3 (clinical investigation) and level 4 
(basic research). In addition, a proportion of journals did not have a research level. Table 3.4 
illustrates the number of papers (n) and the proportion of papers (%) for each research level 
by generation for each of the five clinical advances. A number of observations can be made 
from this table. First, and as illustrated in Figure 3.4, the distribution of papers (across all 
generations) varies between each clinical advance and the portfolio of UK biomedical 
research published between 1988 and 1995. Second, it is notable that over a third of papers 
did not have a research level (and this is, in part, addressed in the following analysis on 
research setting). Finally, as illustrated in Figure 3.4, across all five advances, but especially 
so for replacement surfactant and antenatal steroids, there is a decrease in the proportion of 
papers published in basic journals, ranging from the oldest (generation 4) papers to the more 
recent (generation 1) papers (Figure 3.5). In other words, generation 4 papers are more likely 
to be describing basic research than generation 1 papers. 
 
Setting of research 
Given that over a third of papers did not have a research level (Table 3.4), we decided to try 
and develop a new method based on research setting. This we defined as being in a hospital 
(and thus included the string ‘HOSP’, ‘NHS’ and ‘INFIRM’ in the address field) or in a 
university (and included the string ‘UNIV’, ‘COLL’ and ‘SCH’ in the address field). The results 
of this analysis are presented in Table 3.5. Between 60 per cent (mechanical ventilation and 
antenatal steroids) and 75 per cent (parenteral nutrition) of research occurred in universities, 
while between 26 per cent (antenatal steroids) and 55 per cent (parenteral nutrition) of 
research occurred in hospitals (note that this figures can add up to more than a 100 per cent 
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as research can occur in both places). In developing this methodology, we hypothesized that 
university research may proxy basic research and that hospital research would be 
predominately clinical. It is therefore interesting to note how the proportion of hospital 
research increased from (the oldest) generation 4 papers (e.g. 20 per cent for replacement 
surfactant) to the (most recent) generation 1 papers (e.g. 48 per cent), and this increase is 
consistent over all five advances and ranges between six and 28 percentage points.  
 
Table 3.3:  Distribution of papers by country of publication and mean number of authors 
per paper, by generation and clinical advance 
 
 Authors/ 
paper 
Proportion (%) of papers with address from G7 country 
USA UK Japan France Germany Italy Canada 
Biomedicine (1998) – 41 10 10 6 8 4 5 
         
Mechanical 
ventilation 
G1 4.42 48 10 2 4 12 1 5 
G2 2.32 61 13 2 4 3 1 14 
G3 2.36 68 14 2 2 2 1 11 
G4 5.38 70 12 2 1 2 0 12 
All 4.33 58 12 2 3 6 1 11 
          
Replacement 
surfactant 
G1 3.26 52 7 5 3 9 4 6 
G2 4.41 67 5 5 1 5 1 9 
G3 4.27 72 6 6 0 3 0 11 
G4 3.50 72 6 6 0 2 0 12 
All 3.75 64 6 5 1 6 2 8 
          
Antenatal 
steroids 
G1 3.31 46 11 5 2 4 3 9 
G2 2.89 64 12 2 1 3 1 8 
G3 3.15 73 8 1 3 3 1 9 
G4 3.08 73 6 2 4 3 0 8 
All 3.08 66 9 2 3 3 1 8 
          
Parenteral 
nutrition  
G1 2.59 32 25 0 2 2 0 23 
G2 2.90 40 17 2 5 5 2 24 
G3 1.72 56 20 0 3 3 0 15 
G4 2.20 73 12 0 0 0 0 16 
All 2.47 50 18 1 3 3 1 18 
          
Ultrasound 
G1 1.58 26 19 3 6 5 3 5 
G2 2.48 48 27 1 0 1 2 4 
G3 2.27 47 27 3 1 0 0 9 
G4 2.40 50 27 2 1 0 0 9 
All 2.19 46 23 2 2 1 2 7 
 
30 
Table 3.4:  Research level of papers, by generation and clinical advance 
 
 Research level 
Basic 
(RL = 4) 
Clinical 
investigation 
(RL=2) 
Clinical mix 
(RL=3) 
Clinical 
observation 
(RL = 1) 
Not available 
 
Mechanical 
ventilation 
G1 21 10% 31 14% 56 26% 44 20% 68 31% 
G2 26 9% 27 10% 73 27% 27 10% 121 44% 
G3 45 18% 26 10% 68 27% 18 7% 93 37% 
G4 33 18% 28 15% 46 26% 9 5% 65 36% 
All 86 12% 80 12% 188 27% 81 12% 254 37% 
 
Replacement 
surfactant 
G1 21 8% 95 35% 68 25% 25 9% 60 22% 
G2 43 14% 54 18% 73 24% 11 4% 123 40% 
G3 39 16% 39 16% 49 20% 4 2% 119 48% 
G4 45 21% 39 18% 30 14% 2 1% 99 46% 
All 102 13% 187 24% 159 20% 43 5% 292 37% 
 
Antenatal 
steroids 
G1 27 11% 68 28% 81 33% 15 6% 52 21% 
G2 59 16% 83 22% 88 23% 12 3% 137 36% 
G3 140 18% 178 22% 147 18% 19 2% 317 40% 
G4 198 23% 192 22% 136 16% 11 1% 339 39% 
All 309 18% 408 24% 323 19% 53 3% 602 36% 
 
Parenteral 
nutrition 
G1 1 2% 14 32% 6 14% 11 25% 12 27% 
G2 3 5% 20 32% 11 17% 6 10% 23 37% 
G3 3 5% 14 23% 10 16% 5 8% 29 48% 
G4 2 4% 9 18% 9 18% 3 6% 28 55% 
All 7 4% 47 27% 27 15% 22 13% 72 41% 
 
Ultrasound 
G1 3 3% 3 3% 30 34% 21 24% 31 35% 
G2 16 6% 6 2% 107 39% 35 13% 110 40% 
G3 12 4% 9 3% 110 39% 31 11% 117 42% 
G4 4 2% 10 5% 90 45% 19 9% 78 34% 
All 22 4% 20 3% 251 41% 85 14% 235 38% 
 
NB. The sum of the four generations of papers is greater than all the papers, as some papers can occur 
in multiple generations. 
 
 
31 
Figure 3.4: Proportion of papers by research level for five clinical advances and for UK 
& USA biomedical outputs 
MV= mechanical ventilation; RS = replacement surfactant; AS = antenatal steroids; PN = parenteral 
nutrition; and UL = ultrasound.  (USA and UK data are provided as comparators.) 
 
 
 
Figure 3.5:  Proportion of papers by research level for five clinical advances 
 
MV= mechanical ventilation; RS = replacement surfactant; AS = antenatal steroids; PN = parenteral 
nutrition; and UL = ultrasound.  The numbers refer to generations 1 to 4. For example, RS2 refers to 
replacement surfactant generation 2. 
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Table 3.5:  Research setting of papers, by generation and clinical advance 
 
 Research setting 
University Hospital and 
university Hospital Other 
 
Mechanical 
Ventilation 
G1 149 68% 56 26% 96 44% 30 14% 
G2 141 51% 46 17% 113 41% 65 24% 
G3 154 62% 47 19% 103 41% 39 14% 
G4 116 64% 36 20% 66 37% 33 19% 
All 414 60% 141 20% 289 42% 127 19% 
 
Replacement  
surfactant 
G1 195 72% 88 33% 130 48% 31 12% 
G2 182 60% 70 23% 109 36% 82 17% 
G3 154 62% 39 16% 70 28% 65 16% 
G4 130 60% 25 12% 44 20% 66 31% 
All 494 63% 175 22% 281 36% 177 23% 
 
Antenatal 
steroids 
G1 181 74% 59 24% 89 37% 31 13% 
G2 217 57% 61 16% 120 32% 101 27% 
G3 484 61% 120 15% 206 26% 228 29% 
G4 506 58% 119 14% 186 21% 300 35% 
All 1011 60% 262 15% 437 26% 503 30% 
 
Parenteral 
nutrition 
G1 32 73% 19 43% 26 59% 5 11% 
G2 49 78% 26 41% 34 54% 6 10% 
G3 47 77% 22 36% 29 48% 6 11% 
G4 39 76% 21 41% 27 53% 6 12% 
All 131 75% 74 42% 97 55% 20 12% 
 
Ultrasound 
G1 51 58% 29 33% 54 61% 11 14% 
G2 190 69% 80 29% 137 50% 25 10% 
G3 186 67% 73 26% 132 47% 33 12% 
G4 131 65% 45 22% 89 44% 24 13% 
All 413 67% 169 28% 299 44% 65 11% 
 
NB. The sum of the four generations of papers is greater than all the papers, as some papers can occur 
in multiple generations. 
 
 
Support for research 
The distribution of funding body acknowledgements by sector is shown in Table 3.6. For all 
the cited papers which were found, between 24 per cent (ultrasound) and 38 per cent 
(replacement surfactant) acknowledged the private not-for-profit sector (PNP), between 3 per 
cent (ultrasound) and 22 per cent (parenteral nutrition) industry and between 34 per cent 
(ultrasound) and 66 per cent (antenatal steroids) government. A further 24 per cent 
(replacement surfactant) and 51 per cent (ultrasound) of papers did not have a funding body 
acknowledgement. In the UK these papers are typically published from either NHS hospitals 
or universities, and therefore they may represent public-sector support. Hence the final 
column of data in (‘public’) is the combined output of government and unacknowledged (that 
it, ‘none’).  
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Table 3.6:  Acknowledged funding sector by generation and clinical advance 
 
 Funding acknowledgement 
PNP Industry Government No 
acknowledgment Public 
 
Mechanical 
Ventilation 
G1 59 27% 38 17% 86 39% 96 44% 168 83 
G2 77 28% 55 20% 151 55% 77 28% 205 83 
G3 71 28% 43 17% 156 62% 56 22% 187 84 
G4 49 27% 31 17% 128 71% 33 18% 136 88 
All 194 28% 115 17% 368 53% 215 31% 649 84 
 
Replacement 
surfactant 
G1 86 32% 60 22% 116 43% 105 39% 221 83 
G2 117 38% 55 18% 202 66% 57 19% 259 85 
G3 43 45% 30 12% 199 80% 32 13% 131 93 
G4 89 41% 20 9% 168 78% 35 16% 203 94 
All 248 38% 134 17% 491 63% 188 24% 679 87 
 
Antenatal 
steroids 
G1 79 33% 25 10% 113 47% 87 36% 200 83 
G2 126 33% 35 9% 220 58% 113 30% 333 88 
G3 275 34% 68 9% 549 69% 195 24% 744 93 
G4 333 38% 72 8% 646 74% 179 20% 825 94 
All 610 36% 145 9% 1112 66% 425 25% 1547 91 
 
Parenteral 
nutrition 
G1 10 23% 11 25% 22 50% 21 48% 43 98 
G2 19 30% 19 30% 34 54% 18 29% 52 83 
G3 8 13% 5 8% 25 41% 31 51% 56 92 
G4 11 22% 10 20% 28 55% 19 37% 47 92 
All 43 25% 39 22% 91 52% 65 37% 156 89 
 
Ultrasound 
G1 14 16% 3 3% 19 22% 64 77% 83 99 
G2 70 26% 9 3% 99 36% 130 47% 229 83 
G3 69 25% 10 4% 108 39% 124 46% 237 85 
G4 61 30% 6 3% 83 41% 78 39% 261 80 
All 148 24% 20 3% 207 34% 315 51% 522 85 
 
NB. The sum of the four generations of papers is greater than all the papers, as some papers can occur 
in multiple generations. 
 
 
These numbers fall in the range of UK biomedical outputs in 1995, where 32 per cent of 
papers acknowledged the PNP, 17 per cent industry and 34 per cent government (33 per cent 
of papers have no funding acknowledgment).r In addition to the variation in funding profile for 
each of the clinical advances, it is notable that acknowledged government funding actually 
decreased over the four generations.  
 
 
 
                                               
r  Note that the percentages add up to more than 100 per cent as papers can acknowledge more than one funding sector. 
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Summary 
In this chapter we have developed and applied a new bibliometric protocol to assess the 
scientific basis of neonatal intensive care. By looking at five clinical advances deemed by 
experts to be the most important over the past 30 years, we have analysed how basic 
research has fed into clinical practice and have profiled research outputs at different 
generations. In the next chapter we attempt to interpret these findings and highlight some of 
the limitations associated with this revised methodology. 
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DISCUSSION AND IMPLICATIONS 
 
We began this project two years ago in naive trepidation. As strong advocates for developing 
an evidence base for research policy by researching research, we were fully aware of the 
limitations of Comroe and Dripps’s study. We also knew that the original study took ten years 
to complete and that, sadly, Julius Comroe died during this time. 
 
Therefore in concluding this report, it is perhaps worth noting how Comroe and Dripps 
themselves summed up their original study: 
 
“The conclusions of our study are diametrically opposite to those of Project 
Hindsight, a 1966 study by the Department of Defense (DOD) on research and 
development of military hardware. Because no extensive study of this type had been 
done in the field of biomedical research and development and because such 
research is both time consuming and difficult, many policy makers were satisfied to 
extrapolate the conclusions of the DOD study on military hardware to the entirely 
different field of biomedical research. Without questioning the validity of the DOD 
study, we can now state with confidence that is was incorrect of Presidents, 
Congress and the Office of Management to make this extrapolation.” 
 
We find it striking how we have reached a similar conclusion. Our current study – if not 
‘diametrically opposed’ to the Comroe and Dripps’s work – at least questions the validity of 
their results. We therefore have major concerns that Comroe and Dripps’s findings have, 
seemingly, been ‘extrapolated’ to biomedical science policy as demonstrated by the increased 
support for basic research shown in Figures 1.1–1.4. 
 
At the same time, we are conscious that we have not necessarily met the challenge of 
improving on Comroe and Dripps. We have, in our opinion, indisputably demonstrated that 
their study – as reported – is not repeatable, reliable or valid. However, we would also be the 
first to accept that there are significant limitations to the revised methodology and conclusions 
that we present in this report. That said, we do believe that there are some legitimate policy 
issues that arise from this study and therefore, in this chapter, we highlight the methodological 
challenges and draw out some policy conclusions. 
 
Methodological caveats 
We would highlight three issues that need consideration in interpreting the results of this 
study. The first is the sensitivity of our bibliometric search filters; the second is the 
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measurement of basic and clinical research; the third is the legitimacy of making ‘inter-
advance’ comparisons given that each clinical advance is likely to have a unique development 
cycle, starting at different points in history. 
 
The sensitivity of bibliometric search filters 
As explained in the previous chapter, we adopted a bibliometric approach in defining the 
essential bodies of knowledge of each clinical advance. This permitted us to claim that our 
sample was systematic and transparent in the sense that any other independent researcher 
could use the filters present in Appendix B and the appropriate version of the SCI and repeat 
this study. The disadvantage of this method was that the bibliometric search filters were an 
expert’s opinion of what a particular field (neonatology or obstetrics and gynaecology) looked 
like. Also, as with any keyword search methodology, we are likely to have included some 
papers that were not related to the clinical advance and excluded others that were associated 
with the clinical advance. 
 
Obviously it is not possible to measure those unknown papers, but we could review those 
papers that were identified by the search filter and see which ones were not associated with 
an advance. We therefore looked at antenatal steroids and asked a member of our expert 
advisory group to review the sensitivity of our search filter. We chose antenatal steroids as we 
felt that this would provide a ‘worst-case’ example given that it is based in the intersection of 
two filters with added keywords. Using MEDLINE, we looked up and printed the abstracts of 
all the generation 1 papers. Of the 291 generation 1 papers, 280 were identified on MEDLINE.  
 
These papers where then classified into three groups: 
• antenatal use of steroids (i.e. relevant to development of the lungs in human or animal); 
• postnatal use of steroids (i.e. looking at the effects on lungs, other organs and follow-up); 
• irrelevant, or too distant, from the effects of antenatal steroids on lungs. 
 
This analysis resulted in 56 of the 280 papers (i.e. 20 per cent) being classified as ‘irrelevant’, 
although it is difficult to say whether this is satisfactory and what impact it has on the 
subsequent analyses.  
 
Defining basic and clinical research 
One of the key purposes of this study was to understand the relationship between basic and 
clinical research. Therefore, by necessity, we had to define what we meant by basic and 
clinical research. We used two indicators – research levels and research setting. As explained 
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in Chapter 3, research levels are a crude indicator as they are based on analysis of the journal 
of publication, despite the likelihood that there is variation in the type of research that is 
published in any given journal. Therefore we developed a research setting indicator, which 
was based on the hypothesis that research undertaken in a university was basic, and that 
research undertaken in a hospital setting was clinical. This was an assumption underlying the 
analysis and if wrong, would undermine our conclusions.  
 
The legitimacy of inter-advance comparisons 
One further consideration in interpreting this analysis is that we have compared advances 
cross-sectionally. This is perhaps best illustrated in Figure 4.1, where we have depicted three 
advances as horizontal lines. The first advance (A) has a long history while the third advance 
(C) is a relatively new discovery. The shaded horizontal box is the time period we used to 
define our generation 1 papers, that is publications between 1995 and 1999, while the 
unshaded box illustrates those generation 2–4 papers picked up through the citation tracing 
analysis. 
 
From Figure 4.1 it is apparent that the three advances are at different stages in their 
development cycle at the point of exposure to the bibliometric analysis. Therefore it is likely 
that advance A will be dominated by more clinical papers than advance C. One way to 
calibrate the development process would be to compare the time when an advance was first 
evaluated, using a human population (i.e. through a randomized controlled trial). For example, 
in Figures 2.3 and 2.4 there are boxes relating to human trials. The one for replacement 
surfactant refers to a paper published in 1980,20 while the one for antenatal steroids refers to 
a study published in 1972.21 This would suggest that the development of antenatal steroids 
would be more clinically advanced than replacement surfactant. However, a comparison of 
the data describing research type (Table 3.4 and Figure 3.5) and research setting (Table 3.5) 
reveals that the reverse is true: there are proportionately more, albeit marginally, generation 1 
basic research papers describing antenatal steroids (11 versus 8 per cent; Table 3.4) and 
proportionately fewer generation 1 papers being published from a hospital setting (37 versus 
48 per cent; Table 3.5). 
 
Such an observation is difficult to interpret. It may be because the point of calibration is 
inappropriate. For example, we do know that there was considerable time between the 1972 
trial and the uptake of antenatal steroids in clinical practice and a more appropriate – but 
harder to define – calibration point may be when an advance was first used in a routine non-
evaluative setting. An alternative method (and study) would be to start with more basic or 
early clinical science and try to follow the development, using citation tracing, through to 
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clinical advance. Rather than working back from the desired outcome to the science base, this 
approach would look forward (with hindsight), thus ensuring that all advances are starting at 
the same point in time. Indeed, in collaboration with the Health Economics Research Group at 
Brunel University, we are in the process of piloting such a study that should further inform our 
understanding of the relationship between basic and clinical research. 
 
Figure 4.1: Schema illustrating difficulties in comparing advances 
 
 
 
 
Policy implications 
Because of these methodological limitations, this study may raise more questions than it 
answers. That said, it does raise three important science policy issues that we address below. 
 
Developing public accountability and support for science  
In their concluding chapter Comroe and Dripps have a section entitled Public Support of 
Science. Given that this report was published in 1977, and considering the current debate 
surrounding public engagement in science,22 it is interesting to note Comroe and Dripps’s 
visionary comments that: “Public support of science depends in part on public understanding 
that a major advance is actually the achievement of innumerable scientists…This will require 
some change in science education, from elementary schools through professional medical 
education; in science writing; in the scientist’s presentation of his own work to other scientists 
and to the public.” Indeed, we have argued in the past that we need to undertake research to 
develop our understanding of how research funding impacts on healthcare to enhance public 
perception and understanding of biomedical science and the scientific process.16, 17 
Given these comments, it was serendipitous that, in the process of the current study, we 
identified an exemplar of how basic research feeds into clinical research and healthcare. The 
work of Liggins (1969) was originally funded by the Wellcome Trust and examined how, when 
glucocorticoids triggered the onset of labour in pregnant sheep, the lambs born prematurely 
Advance A 
Advance B 
Advance C 
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had well aerated lungs, while many of the control animals died of respiratory distress 
syndrome (RDS).23 It is possible to trace this original, basic scientific, observation from animal 
studies, through to randomized controlled trials on humans, (systematic) literature reviews, 
economic evaluations, policy recommendations, practice reviews and, more recently, analysis 
of research payback. Today, in the UK, the use of corticosteroids (described as ‘antenatal 
steroids’ by our Delphi survey participants), is the norm when preterm delivery is expected.24  
An NIH economic assessment claimed that, between 1976 and 1983, US$7.4 million was 
spent on research evaluating the use of antenatal steroids and, in terms of reduced treatment 
costs, this produced a potential annual saving of between US$16.5 million and US$145.1 
million. The complexity of some of the various stages of this advance were demonstrated in 
initial payback analysis,25 but will be described in a forthcoming paper.26 However, this 
example is particularly interesting for a number of reasons. First, the original research was 
sponsored by the Wellcome Trust and presents an excellent ‘good news story’ for promoting 
the work of the Trust. Second, if it were not for the use of animal models the clinical advance, 
and associated health benefit, is unlikely to have occurred, and therefore this case study 
illustrates the need for, and the use of, animals in research. Thirdly, there was a considerable 
time lag between the basic research (1969) to development and widespread clinical use 
(1999), illustrating the slow and incremental nature of much of scientific progress. Finally, the 
development and ultimate success (in terms of improving human and animal health) of the 
basic research described by Liggins (1969) could not have been predicted at the time of the 
study. 
 
The time between discovery and application 
As this study has shown, the process of following an initial discovery through to clinical 
advance is highly complex. One of the most striking features of our analysis was how similar 
the knowledge cycle time was across the five clinical advances (Table 3.2 and Figures 3.3a–
e). The overall median time of publication between the (oldest) generation 4 papers and the 
(more recent) generation 1 papers was 13 years for artificial surfactant, 17 years for 
mechanical ventilation, antenatal steroids and ultrasound, and 21 years for parenteral 
nutrition. This is nearly identical to the findings of a methodologically similar, but independent, 
study that used clinical guidelines16, 17 and showed that it takes about 17 years for the fourth-
generation research papers to feed into a clinical guideline. From a policy viewpoint, this begs 
the questions as to what is the optimum time for research to be fully evaluated and put into 
practice, and whether this process needs to and can be speeded up. 
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Role of basic science in supporting clinical advance 
The relationship between basic research, and how it supports clinical research, is at the core 
of any biomedical research strategy. The unifying mission of all biomedical research funders is 
to improve healthcare. As we have seen in Chapter 1 (Figures 1.1–1.4), support for basic 
research is high and has been on the increase for the past decade.  
 
Using the revised bibliometric protocol, we have shown in this study that after four generations 
of citation, between 2 per cent and 21 per cent of research was basic (Table 3.4). This 
corroborates the findings of the clinical guidelines study16, 17 that showed that after four 
generations of citation only 8 per cent of research was basic. These two observations are at 
odds with Comroe and Dripps’s finding that 40 per cent of all research articles judged to be 
essential for latter clinical advance were not clinically oriented at the time of the study, thus 
undermining the evidence base that has, in the past, supported the increased funding of basic 
research. 
 
We are not arguing that research funders should not be supporting basic research, but we are 
making the case that there needs to be a greater understanding of how basic research 
supports clinical advances and, in light of these conclusions, a critical reappraisal of current 
research funding priorities. Indeed, perhaps it is the advocacy of evidence-based policy that 
confirms Comroe and Dripps’s work as truly seminal. 
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APPENDIX A:  QUESTIONNAIRE 
 
 
 
 
 
 
 
 
Factors that lead to advances in neonatal intensive care 
 
 
Instructions for participants 
 
 
The purpose of this questionnaire is to identify the most important advances that have 
occurred in the development of neonatal intensive care since 1960.  We wish to 
ensure that the resulting list of the most important advances reflects the considered 
opinion of experts within this speciality. 
 
Please indicate the ten advances that you believe have been most important in the 
development of neonatal intensive care from 1960 onwards.  Please do not prioritise 
your choices.   
 
The definition of neonatal intensive care we are working to is,  
 
‘The nursing and medical care required for a neonate where 
one or more organ systems require continuous support and 
monitoring’ 
 
Please return to The Wellcome Trust in the prepaid envelope, or by fax (0171 
6118742) by Friday 15th October, or at your earliest convenience. 
 
We look forward to receiving your responses. 
 
If you have any queries regarding the completion of this questionnaire, please contact 
Elizabeth Green or Barbara Mason, Research Officers, on 0171 6117206. 
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Name   
 
Job Title   
 
Length of time in the field  (Years) 
 
Please tick the ten most important advances 
 
Phototherapy  
 
 
Total Parental Nutrition  
 
 
Increased understanding of the physiology of the neonate  
 
 
Recognition of the importance of early feeding  
 
 
Temperature control  
 
 
Development of neonatalogy as a subspeciality (training of clinicians and 
nurses devoted to this field) 
 
 
 
Development of artificial Surfactant   
 
 
Use of antenatal steroids  
 
 
Development of neonatal intensive care ‘units’  
 
 
Communication and collaboration between obstetrician and paediatrician  
 
 
Antibiotics for the newborn  
 
 
Mechanical ventilation  
 
 
Use of antenatal steroids  
 
 
Improved resuscitation techniques  
 
 
Endotracheal intubation  
 
 
Continuouis monitoring of vital signs  
 
 
Involvement of parents in care and decision making  
 
 
Ultrasound imaging  
 
 
Surgical techniques specifically for neonates  
 
 
Follow-up studies of very low birth weight and preterm babies  
 
 
Monitoring methods specifically designed for babies  
 
 
Introduction of plastic tubing, cannulas etc.  
 
 
Measurement of biochemical variables of neonates  
 
 
Use of incubators  
 
 
Transport of mothers and babies at risk  
 
 
CPAP  
 
 
Management of neonatal jaundice  
 
 
Use of microsamples for pathological analysis  
 
Thank you for your assistance. 
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APPENDIX B: BIBLIOMETRIC SEARCH FILTERS 
 
 
B1  Neonatology filter 
 
1. Field:: Abbr journal 
Statement:: BIOL-NEONATE OR CLIN-PERINATOL OR EARLY-HUM-DEV OR J-          
PERINATAL-MED                                                  
2. Field:: Abbr journal 
Statement:: ACTA-PAEDIAT OR ARCH-DIS-CHILD OR ARCH-PEDIATR-ADOLESC-MED OR 
ARCHIVES-PEDIATRIE OR CHILD-NERV-SYST OR CLIN-PEDIAT OR DEVELOP-MED-
CHILD-NEUROL OR EUR-J-PEDIAT                       
3. Field:: Abbr journal 
Statement:: EUR-J-PEDIATR-SURG OR INT-J-PED-OTORHINOLARYNGOL OR J-CHILD-  
NEUROL OR J-DENT-CHILD OR J-PAEDIATR-CHILD-HEALTH OR J-PEDIAT OR J-PEDIAT-
ENDOCRINOL OR J-PEDIAT-GASTROENTEROL-NUTR OR J-PEDIAT-HEMATOL-ONCOL 
OR J-PEDIAT-SURG  
4. Field:: Abbr journal 
Statement:: J-PEDIATR-ENDOCRINOL-METAB OR J-TROP-PEDIAT OR MED-PEDIAT-   
ONCOL OR NEUROPEDIATRICS OR PAEDIATR-PERINAT-EPIDEMIOL OR PEDIAT-
CARDIOL OR PEDIAT-CLIN-N-AMER OR PEDIAT-INF-DIS-J OR PEDIAT-NEUROSURG OR 
PEDIAT-PULM                        
5. 5)Field:: Abbr journal 
Statement:: PEDIAT-RADIOL OR PEDIAT-RES OR PEDIATR-HEMATOL-ONCOL OR 
PEDIATR-PATHOL-LAB-MED OR PEDIATRICS OR J-DEVELOP-PHYSIOL      
6. Field:: Title        
Statement:: APNEA OR ASPHYXIA OR HYPOXIA OR IMMATUR* OR PREMATUR* OR   
RESPIRATORY DISTRESS SYNDROME OR RETINOPATH* OR SURFACTANT     
7. Field:: Set          
Statement:: 6 AND (2 THRU 5)                                              
8. Field:: Title        
Statement:: AFTER BIRTH OR BIRTH RELATED OR (BIRTH* AND WEIGH* AND (G OR  
LESS)) OR BRONCHOPULMONARY DYSPLASIA OR ECMO OR ELBW OR 
EXTRACORPOREAL MEMBRANE OXYGENATION OR (FIRST MONTH AND LIFE) OR FULL 
TERM                                                   
9. Field:: Title 
Statement:: ((FETAL OR FETUS) AND (BREATHING OR CEREBRAL OR HYPOXIA OR    
LUNG OR NMDA OR OXYGEN* OR TERM)) OR HUMAN MILK OR HYPOXI* ISCHEMI* OR 
INFANT FORMULA OR (INFANT* AND TERM) OR INFANT* DELIVER*                         
10. Field:: Title        
Statement:: ((INTRAVENTRICULAR OR PERIVENTRICULAR) AND (HEMORRHAGE OR   
LEU*OMALACIA)) OR LBW OR LOW BIRTH WEIGHT OR MECONIUM ASPIRATION OR 
MILK FORMULA* OR NEAR TERM OR NECROTIZING ENTEROCOLITIS OR NEONAT* OR 
NEWBORN*  
 
46 
                                                                                                                                                
 
11. Field:: Title        
Statement:: PERINATAL OR POSTHEMORRHAGIC HYDROCEPHALUS OR POSTNATAL OR 
   PRE TERM OR (PREMATUR* AND (INFANT* OR RETINOPATHY)) OR   (PRENATAL NOT 
(DETECT* OR DETERMIN* OR DIAGNOS* OR SCREEN*))  OR PRETERM                               
                      
12. Field:: Title        
Statement:: (PROGRAM* AND (METABOLISM OR NUTRITION* OR PROTEIN)) OR 
PULMONARY HEMORRHAGE OR SGA OR SMALL FOR GESTATIONAL AGE OR VLBW        
                              
13. Field:: Title       
Statement:: CHICK* OR EMBRYO*                                              
14. Field:: Set   
Statement:: (1 OR (7 THRU 12)) NOT 13                                      
15. Field:: Set        
Language:: <No Limit>                
Doctype:: Article 
Update:: <No Limit>     
Statement:: 14                                                             
16. Field:: Set          
Doctype:: Note 
Statement:: 14                                                             
17. Field:: Set          
Doctype:: Review 
Statement:: 14                                                             
18. Field:: Set         
Statement:: 15 THRU 17                                                     
 
 
 
 
B2  Obstetrics/Gynaecology filter 
 
1. Field:: Abbr journal 
Statement:: ACTA-OBSTET-GYNECOL-SCAND OR AMER-J-OBSTET-GYNECOL OR AMER-
J- REPROD-IMMUNOL OR ARCH-GYNECOL-OBSTET OR BAILLIERE-CLIN-OBSTET-GYN 
OR BRIT-J-OBSTET-GYNAECOL OR CLIN-OBSTET-GYNECOL OR CLIN-PERINATOL OR 
CONTRACEPTION                            Field:: Abbr journal 
2. Field:: Abbr journal 
Statement:: EUR-J-OBSTET* OR FERT-STERIL OR GEBURTSH-FRAU* OR GYNECOL- 
OBSTET-INVEST OR GYNECOL-ONCOL OR HUM-REPROD OR HYPERTENS-PREGNANCY 
OR INT-J-FERTIL-MENOPAUSAL-STUD OR INT-J-GYNECOL- CANCER OR INT-J-
GYNECOL-OBSTET OR INT-J-GYNECOL-PATHOL         
3. Field:: Abbr journal 
Statement:: J-GYNECOL-SURG OR J-REPROD-IMMUNOL OR J-REPROD-MED OR J-SOC- 
GYNECOL-INVESTIGATION OR MOL-REPROD-DEV OR OBSTET-GYNECOL OR  OBSTET-
GYNECOL-CLIN-N-AMER OR PLACENTA OR PRENATAL-DIAG OR REPROD-FERT-
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DEVELOP OR REPROD-TOXICOL 
                          
4. Field:: Title    
Statement:: ABORTION* OR AMNIO* OR ANDROGEN OR ANTENATAL OR BARTHOLIN* OR 
(BIRTH NOT (CHILD* OR INFANT*)) OR (CERVICAL NOT (HEAD OR NECK OR SPIN* OR 
VERTEBRA*))                                   
5. Field:: Title        
Statement:: CERVIX OR CESAREAN OR CHORIONIC OR CLITOR* OR COLPO* OR       
CONTRACEPTI* OR DECIDUA* OR DYSTOCIA OR ECLAMPSIA OR ENDOMETRI* OR 
ESTRADIOL OR ESTROGEN OR FALLOPIAN OR FETAL OR FETUS* OR GESTATION* OR 
GONAD* OR GRANULOSA OR GYNECOLOG*      
6. Field:: Title        
Statement:: HYSTERECTOMY OR INSEMINAT* OR INTRAFALLOPIAN OR INTRAUTERINE  
OR INTRAVAGINAL OR LH OR LUTEAL OR LUTEINIZING OR MENOPAUS*   OR 
MENSTRUA* OR MYOMETRI* OR OBSTETRIC* OR OVAR* OR OVULAT*  OR OXYTOCIN 
OR PARTURITION OR PELLUCIDA OR PELVIC              
7. Field:: Title        
Statement:: PERINATAL OR PLACENTA* OR POSTHYSTERECTOMY OR POSTPARTUM OR 
  PREECLAMP* OR PREGNANC* OR PREGNANT OR PREMENOPAUSAL OR 
PREMENSTRUAL OR PRENATAL OR PRETERM OR PROGEST* OR  PROSTAGLANDIN*     
                                           
8. Field:: Title        
Statement:: TRANSPLACENTAL OR TRANSVAGINAL OR TRIMESTER OR TROPHOBLAST*  
 OR TUBAL OR UMBILICAL OR UTERINE OR UTERO* OR UTERUS OR VAGINA* OR VULVA  
9. Field:: Set          
Statement:: 1 THRU 8                                                       
10. Field:: Set          
Doctype:: Article 
Statement:: 9 
                                                              
11. Field:: Set          
Doctype:: NOTE 
Statement:: 9                                                              
12. Field:: Set          
Doctype:: Review 
Statement:: 9                                                              
13. Field:: Set          
Statement:: 10 THRU 12                                                     
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B3  Key words used in SCI database search 
 
  
Antenatal steroids Betamethasone 
Dexamethasone 
Antenatal steroids 
Antenatal corticosteroids 
Mechanical ventilation Ventil* 
(use of wild card to capture all forms of 
ventilate/ventilation) 
Replacement surfactant Hyaline 
Surfactant 
Surface tension 
Parenteral nutrition Parenteral 
Ultrasound Ultrasound 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
